Rare Disease Treatment Market Rising Trends, Territorial Outlook and Industry Growth Prospects 2020-2026

 The Rare Disease Treatment Market is poised to accumulate noteworthy gains in coming years owing to the growing prevalence of rare diseases across the world. As per National Institutes of Health, nearly 30 million people in America suffer from one of the 7,000 rare diseases with only 5% of the rare disorders having substantial treatment options. The surging focus on research activities and development of novel therapeutic drugs has further elevated the rare disease treatment market value.

Favorable government policies and measures for the treatment of rare disorders will also contribute towards market growth in the years to come. These initiatives are driving new drug launches across developed regions, which is expected to positively impact the rare disease treatment market growth. In fact, major diagnostic companies have been actively engaged in expanding their product portfolio recently. Citing an instance, in November 2020, Amylyx Pharmaceuticals, a leading pharmaceuticals company focused towards development of novel treatments for Alzheimer’s disease, ALS, as well as other neurodegenerative diseases, reportedly announced that its drug candidate for treating Wolfram syndrome, AMX0035, was granted orphan drug designation by the U.S. FDA.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/3873

AMX0035 is specifically designed to target ER stress, with preclinical data suggesting that it might be a highly promising approach to stop the irreversible optic nerve atrophy progression in Wolfram syndrome patients.

 

Global Market Insights, Inc., estimates that the rare disease treatment market would surpass $317 billion by 2026.

 

With respect to route of administration, in 2019, the oral route of administration segment held a considerable market share and exceeded a valuation of more than $80.2 billion. Oral route of administration is highly preferred for consumption of drug since it is convenient, cost-effective, and non-invasive in comparison to other injectable administration. The segment is also driven by the additional benefits associated with the administration method, such as ease of ingestion, and safety of patients. Consequently, preference for the oral route of administration is rapidly increasing among patients, which would effectively lead to substantial development of novel oral drugs.

 

On the geographical front, Brazil dominated the overall rare disease treatment market in Latin America and is estimated to expand at a CAGR of more than 12.8% over the projected time frame. This anticipated growth is ascribed to the improving public healthcare infrastructure across the country. Regional government authorities are introducing various measures to focus on treatment of rare diseases. The Brazilian Health Authorities (ANVISA) has set up a standard procedure for the approval of clinical trials for the treatment, diagnosis, as well as prevention of rare diseases. In addition, major key players in the country are actively focusing towards the development of new therapeutic drugs. The afore-mentioned factors are likely to fuel the regional rare diseases treatment market growth in the years to come.

 

Request for customization @ https://www.gminsights.com/roc/3873

 

At present, prominent industry players are implementing numerous strategic initiatives such as mergers, partnerships, and collaborations in order to expand their offerings and subsequently strengthen their presence in the market. Citing an instance, in November 2020, Evox Therapeutics Ltd, a renowned exosome therapeutics company, reportedly announced the launch of a new collaboration largely focused on rare diseases with the Oxford-Harrington Rare Disease Centre, University of Oxford rooted within the Pediatrics department.

 

This collaboration would run over a period of three years and would capitalize on the top-class research environment in Oxford, using exosome therapeutics expertise as well as resources from both the University and Evox to fuel innovation within rare disease drug development.

Such unique collaborations would bring in new treatment options and further shape the market in the coming years.

 

Eli Lilly and Company, Bayer AG, Sanofi, Actelion Pharmaceuticals Ltd, Novartis AG, Celgene Corporation, AbbVie Inc., Johnson & Johnson Services, Inc., Alexion Pharmaceuticals, Inc., and Pfizer Inc among many others are some of the key players operating in the rare disease treatment market.

 

Browse key industry insights spread across 230 pages with 231 market data tables and 18 figures & charts from the report, Rare Disease Treatment Market in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/rare-disease-treatment-market

Report Content

Chapter 3   Rare Disease Treatment Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2015 - 2026 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1    Increase in number of rare disease cases across the globe

3.3.1.2    Favourable government policies

3.3.1.3    Growing number of new drug launches

3.3.1.4    Increasing R&D activities for novel therapeutics and drugs

3.3.2    Industry pitfalls & challenges

3.3.2.1    Lack of awareness regarding rare disease treatment

3.3.2.2    High cost of the drugs and therapy

3.4    Growth potential analysis

3.4.1    By drug type

3.4.2    By therapeutic area

3.4.3    By patient

3.4.4    By route of administration

3.5    COVID-19 impact analysis

3.6    Regulatory landscape

3.6.1    U.S.

3.6.2    Europe

3.6.3    Asia Pacific

3.7    Porter’s analysis

3.8    Competitive landscape, 2019

3.8.1    Competitive matrix analysis

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

 

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com